Skip to content
value.today

Alexza Pharmaceuticals Inc.

Total raised
$37 M
5 rounds on record
Latest round
$5 M
Feb 2016
First round on record
Oct 2009
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Alexza Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2016$5 MNo. 5$2 to $10 million

Alexza Pharmaceuticals Inc.: Raise no. 5, Feb 2016

Investors in this round

1 investor had bought by the notice of Feb 24, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edwin S Kamemoto · Executive Officer
  • Thomas B King · Executive Officer, Director
  • Deepika R Pakianathan · Director
  • Gordon Leighton Ringold · Director
  • Isaac Leighton Stein · Director
  • J Kevin Buchi · Director
  • J Leighton Read · Director
  • Joseph L Turner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Shares issued in consideration of reduction in outstanding balance of a note dated 5/07/13 by $5,000,000 and forgiveness of accrued and unpaid interest thereunder as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on 2/24/2016”

Signed by Thomas B. King, Pres & CEO. Source: SEC Form D, newest notice filed Feb 24, 2016. Read the notice at the SEC.

equitySEC
Oct 2014$8 MNo. 4$2 to $10 million

Alexza Pharmaceuticals Inc.: Raise no. 4, Oct 2014

Investors in this round

1 investor had bought by the notice of Oct 28, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edwin S Kamemoto · Executive Officer
  • James V Cassella · Executive Officer
  • Mark K Oki · Executive Officer
  • Robert A Lippe · Executive Officer
  • Thomas B King · Executive Officer, Director
  • Deepika R Pakianathan · Director
  • Gordon Leighton Ringold · Director
  • Isaac Leighton Stein · Director
  • J Kevin Buchi · Director
  • J Leighton Read · Director
  • Joseph L Turner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas B. King, Pres & CEO. Source: SEC Form D, newest notice filed Oct 28, 2014. Read the notice at the SEC.

equitySEC
Mar 2012$3 MNo. 3$2 to $10 million

Alexza Pharmaceuticals Inc.: Raise no. 3, Mar 2012

Investors in this round

1 investor had bought by the notice of Mar 16, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • James V Cassella · Executive Officer
  • Mark K Oki · Executive Officer
  • Michael J Simms · Executive Officer
  • Thomas B King · Executive Officer, Director
  • Andrew L Busser · Director
  • Deepika R Pakianathan · Director
  • Gordon Leighton Ringold · Director
  • Hal V Barron · Director
  • Isaac Leighton Stein · Director
  • J Leighton Read · Director
  • Joseph L Turner · Director
  • Samuel D. Colella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas B King, President & Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 16, 2012. Read the notice at the SEC.

equitySEC
May 2010$1 MNo. 2Under $2 million

Alexza Pharmaceuticals Inc.: Raise no. 2, May 2010

Investors in this round

1 investor had bought by the notice of May 12, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • August J Moretti · Executive Officer
  • James V Cassella · Executive Officer
  • Michael J Simms · Executive Officer
  • Thomas B King · Executive Officer, Director
  • Alan D Frazier · Director
  • Andrew L Busser · Director
  • Deepika R Pakianathan · Director
  • Gordon Leighton Ringold · Director
  • Hal V Barron · Director
  • Isaac Leighton Stein · Director
  • J Leighton Read · Director
  • Samuel D Colella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas B King, President & Chief Executive Officer. Source: SEC Form D, newest notice filed May 12, 2010. Read the notice at the SEC.

optionsSEC
Oct 2009$20 MNo. 1$10 to $50 million

Alexza Pharmaceuticals Inc.: Raise no. 1, Oct 2009

Investors in this round

30 investors had bought by the notice of Oct 6, 2009: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$551,028
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • August J Moretti · Executive Officer
  • James V Cassella · Executive Officer
  • Michael J Simms · Executive Officer
  • Thomas B King · Executive Officer, Director
  • Alan D Frazier · Director
  • Andrew L Busser · Director
  • Deepika R Pakianathan · Director
  • Gordon Leighton Ringold · Director
  • Hal V Barron · Director
  • Isaac Leighton Stein · Director
  • J Leighton Read · Director
  • Samuel D Colella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • RBC Capital Markets Corporation (CRD 31194) · broker-dealer RBC Capital Markets Corporation (CRD 31194) · San Francisco, CaSold in no state named

Signed by Thomas B King, President & Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 6, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Alexza Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2016).

    SEC Form D · Feb 2016

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2016

That is all the official record says: Alexza Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Alexza Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 30 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Alexza Pharmaceuticals Inc.
NameRoleNamed in
Edwin S KamemotoExecutive officerFeb 2016
Thomas B KingExecutive officerFeb 2016
James V CassellaExecutive officerOct 2014
Mark K OkiExecutive officerOct 2014
Robert A LippeExecutive officerOct 2014
Michael J SimmsExecutive officerMar 2012
August J MorettiExecutive officerMay 2010
Deepika R PakianathanDirectorFeb 2016
Gordon Leighton RingoldDirectorFeb 2016
Isaac Leighton SteinDirectorFeb 2016
J Kevin BuchiDirectorFeb 2016
J Leighton ReadDirectorFeb 2016
Joseph L TurnerDirectorFeb 2016
Thomas B KingDirectorFeb 2016
Andrew L BusserDirectorMar 2012
Hal V BarronDirectorMar 2012
Samuel D. ColellaDirectorMar 2012
Alan D FrazierDirectorMay 2010
Samuel D ColellaDirectorMay 2010